TransMedics delivered a stellar Q1, beating revenue and EPS estimates, and raised FY25 guidance, showcasing robust growth and execution. I see significant upside from expanding organ utilization, especially with the upcoming kidney market and international opportunities, which meaningfully increase TAM. Despite risks like share dilution, logistics complexity, and regulatory hurdles, TMDX's moat...
ANDOVER, Mass. , May 20, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences.
While being an innovative company doesn't guarantee superior long-term returns, it doesn't hurt those chances either. In fact, when a corporation is making important breakthroughs and boasts significant growth prospects in its industry, that could translate to above-average stock market performances over five years or more.
Shares of TransMedics Group (TMDX 6.54%) recently bounded higher in response to a first-quarter earnings report that was a lot better than investors were expecting. Downward revenue guidance revisions and unwanted attention from short-sellers pushed the stock down late last year, but things are looking up.
Shares of next-generation transplant technology platform TransMedics (TMDX 21.72%) were up 21% as of noon ET on Friday, according to data provided by S&P Global Market Intelligence.
TransMedics reported extremely strong Q1 results, alleviating concerns from a weak Q3 2024 and a short attack in January. The company continues to expand its logistics capabilities and should see a boost from new heart and lung devices later in the year. While new perfusion devices are set to enter the market, TransMedics' competitive positioning appears to be extremely strong.
TransMedics Group, Inc. (NASDAQ:TMDX ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Laine Morgan - Gilmartin Group, Investor Relations Waleed Hassanein - President & Chief Executive Officer Gerardo Hernandez - Chief Financial Officer Conference Call Participants Allen Gong - JPMorgan Bill Plovanic - Canaccord Justin Wang - Morgan Stanley Chris Pasquale - Nephron ...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.